4SC AG Média de recomendação
Qual é o Média de recomendação de 4SC AG?
O Média de recomendação de 4SC AG é 1.00
Qual é a definição de Média de recomendação?
A média da recomendação é a média das classificações dos analistas das ações, variando de 1,0 (compra forte) a 5,0 (venda forte).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Média de recomendação de empresas na Setor Health Care em XETRA em comparação com 4SC AG
O que 4SC AG faz?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Empresas com média de recomendação semelhantes a 4SC AG
- 4SC AG tem Média de recomendação de 1.00
- JOYY Inc tem Média de recomendação de 1.05
- Honda Motor tem Média de recomendação de 1.06
- Ares Capital Corp tem Média de recomendação de 1.07
- Petroleo Brasileiro S.A. Petrobras tem Média de recomendação de 1.08
- VNET Inc tem Média de recomendação de 1.08
- Rocket Pharmaceuticals Inc tem Média de recomendação de 1.08